Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy

Clinical Nutrition

Volumn 32, Issue 6, 2013, Pages 894-903

  Lecumberri, Elena ^a   Dupertuis, Yves Marc ^a   Miralbell, Raymond ^a   Pichard, Claude ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Adjuvant; Cancer therapy; Epigallocatechin 3 gallate; Green tea; Side effects

Indexed keywords

ARSENIC TRIOXIDE; BLEOMYCIN; BORTEZOMIB; CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; CASPASE 3; CELECOXIB; CISPLATIN; DAUNORUBICIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUCOSE REGULATED PROTEIN 78; GLYCOPROTEIN P INHIBITOR; IRINOTECAN; MATRIX METALLOPROTEINASE; PACLITAXEL; SCATTER FACTOR; SEMAXANIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN C; VORINOSTAT;

ADJUVANT THERAPY; ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CARDIOTOXICITY; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; COLON CANCER; COLON HEMORRHAGE; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; EDEMA; ENDOTOXEMIA; GAMMA RADIATION; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LEUKOPENIA; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG FIBROSIS; MELANOMA; NEOPLASM; NEPHROTOXICITY; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; SALIVARY GLAND DISEASE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; STOMACH ULCER; TEA; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; WEIGHT REDUCTION; X RAY;

5-FLUOROURACIL; 5-FU; ADJUVANT; ARSENIC TRIOXIDE; ATO; CANCER THERAPY; CISPLATIN; CP; DAUNORUBICIN; DAUNORUBICINOL; DNR; DNROL; DOX; DOXORUBICIN; EGCG; EPIGALLOCATECHIN-3-GALLATE; GREEN TEA; HBMEC; HNE; HORMONE REFRACTORY PROSTATE CANCER; HRPC; HUMAN BRAIN MICROVASCULAR ENDOTHELIAL CELLS; HYDROXYNONENAL; IL; INTERLEUKIN; IONIZING RADIATION; IR; REACTIVE OXYGEN SPECIES; ROS; SIDE EFFECTS; TRICHOSTATIN A; TSA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATECHIN; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYPHENOLS; TEA;

EID: 84887623713     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.03.008     Document Type: Review

References (50)

1. Yang C.S., Wang H., Li G.X., Yang Z., Guan F., Jin H. Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res 2011, 64(2):113-122.
2. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011, 82(12):1807-1821.
3. Suganuma M., Saha A., Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 2011, 102(2):317-323.
4. Wessner B., Strasser E.M., Koitz N., Schmuckenschlager C., Unger-Manhart N., Roth E. Green tea polyphenol administration partly ameliorates chemotherapy-induced side effects in the small intestine of mice. JNutr 2007, 137(3):634-640.
5. Qiao J., Gu C., Shang W., Du J., Yin W., Zhu M., et al. Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines invitro. Food Chem Toxicol 2011, 49(6):1410-1415.
6. Stearns M.E., Amatangelo M.D., Varma D., Sell C., Goodyear S.M. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth insevere combined immunodeficiency mice. Am J Pathol 2010, 177(6):3169-3179.
7. Liang G., Tang A., Lin X., Li L., Zhang S., Huang Z., et al. Green tea catechins augment the antitumor activity of doxorubicin in an invivo mouse model for chemoresistant liver cancer. Int J Oncol 2010, 37(1):111-123.
8. Farabegoli F., Papi A., Bartolini G., Ostan R., Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010, 17(5):356-362.
9. Stearns M.E., Wang M. Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl Oncol 2011, 4(3):147-156.
10. Nihal M., Roelke C.T., Wood G.S. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). Pharm Res 2010, 27(6):1103-1114.
11. Mohan N., Karmakar S., Banik N.L., Ray S.K. SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. Neurochem Res 2011, 36(8):1383-1396.
12. Tang S.N., Fu J., Shankar S., Srivastava R.K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One 2012, 7(2):e31067.
13. Huang K.H., Kuo K.L., Chen S.C., Weng T.I., Chuang Y.T., Tsai Y.C., et al. Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS One 2012, 7(3):e33615.
14. Bachmeier B., Fichtner I., Killian P.H., Kronski E., Pfeffer U., Efferth T. Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One 2011, 6(5):e20550.
15. Chen T.C., Wang W., Golden E.B., Thomas S., Sivakumar W., Hofman F.M., et al. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 2011, 302(2):100-108.
16. Luo T., Wang J., Yin Y., Hua H., Jing J., Sun X., et al. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 2010, 12(1):R8.
17. Huang W., Ding L., Huang Q., Hu H., Liu S., Yang X., et al. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology 2010, 52(2):703-714.
18. Tu S.H., Ku C.Y., Ho C.T., Chen C.S., Huang C.S., Lee C.H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced alpha9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol Nutr Food Res 2011, 55(3):455-466.
19. Farabegoli F., Barbi C., Lambertini E., Piva R. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev 2007, 31(6):499-504.
20. Li Y., Yuan Y.Y., Meeran S.M., Tollefsbol T.O. Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol Cancer 2010, 9:274.
21. Chuu C.P., Chen R.Y., Kokontis J.M., Hiipakka R.A., Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 2009, 275(1):86-92.
22. Siddiqui I.A., Asim M., Hafeez B.B., Adhami V.M., Tarapore R.S., Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011, 25(4):1198-1207.
23. Lambert J.D., Elias R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 2010, 501(1):65-72.
24. Chan M.M., Soprano K.J., Weinstein K., Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. JCell Physiol 2006, 207(2):389-396.
25. Lee T.C., Cheng I.C., Shue J.J., Wang T.C. Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells. Toxicol Appl Pharmacol 2011, 250(1):69-77.
26. Hwang J.T., Ha J., Park I.J., Lee S.K., Baik H.W., Kim Y.M., et al. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 2007, 247(1):115-121.
27. Bannerman B., Xu L., Jones M., Tsu C., Yu J., Hales P., et al. Preclinical evaluation of theantitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 2011, 68(5):1145-1154.
28. Ge J., Tan B.X., Chen Y., Yang L., Peng X.C., Li H.Z., et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. JMol Med (Berl) 2011, 89(6):595-602.
29. McLaughlin N., Annabi B., Bouzeghrane M., Temme A., Bahary J.P., Moumdjian R., et al. The survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Res 2006, 1071(1):1-9.
30. Baatout S., Jacquet P., Derradji H., Ooms D., Michaux A., Mergeay M. Study of the combined effect of X-irradiation and epigallocatechin-gallate (a tea component) on the growth inhibition and induction of apoptosis in human cancer cell lines. Oncol Rep 2004, 12(1):159-167.
31. McLaughlin N., Annabi B., Lachambre M.P., Kim K.S., Bahary J.P., Moumdjian R., et al. Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death. JNeurooncol 2006, 80(2):111-121.
32. Zhang G., Wang Y., Zhang Y., Wan X., Li J., Liu K., et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med 2012, 12(2):163-176.
33. Lee H.J., Kim J.S., Moon C., Kim J.C., Lee Y.S., Jang J.S., et al. Modification of gamma-radiation response in mice by green tea polyphenols. Phytother Res 2008, 22(10):1380-1383.
34. Abboud P.A., Hake P.W., Burroughs T.J., Odoms K., O'Connor M., Mangeshkar P., et al. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol 2008, 579(1-3):411-417.
35. Sergent T., Piront N., Meurice J., Toussaint O., Schneider Y.J. Anti-inflammatory effects of dietary phenolic compounds in an invitro model of inflamed human intestinal epithelium. Chem Biol Interact 2010, 188(3):659-667.
36. Hu Y., Cao J.J., Liu P., Guo D.H., Wang Y.P., Yin J., et al. Protective role of tea polyphenols in combination against radiation-induced haematopoietic and biochemical alterations in mice. Phytother Res 2011, 25(12):1761-1769.
37. Li W., Ashok M., Li J., Yang H., Sama A.E., Wang H. Amajor ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2007, 2(11):e1153.
38. Annabi B., Lee Y.T., Martel C., Pilorget A., Bahary J.P., Beliveau R. Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (-) epigallocatechin-3-gallate. Cancer Biol Ther 2003, 2(6):642-649.
39. Alcaraz M., Armero D., Martinez-Beneyto Y., Castillo J., Benavente-García O., Fernandez H., et al. Chemical genoprotection: reducing biological damage to as low as reasonably achievable levels. Dentomaxillofac Radiol 2011, 40(5):310-314.
40. Pajonk F., Riedisser A., Henke M., McBride W.H., Fiebich B. The effects of tea extracts on proinflammatory signaling. BMC Med 2006, 4:28.
41. Khan S.A., Priyamvada S., Khan W., Khan S., Farooq N., Yusufi A.N. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol Res 2009, 60(5):382-391.
42. Sahin K., Tuzcu M., Gencoglu H., Dogukan A., Timurkan M., Sahin N., et al. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci 2010, 87(7-8):240-245.
43. El-Mowafy A.M., Al-Gayyar M.M., Salem H.A., El-Mesery M.E., Darweish M.M. Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 2010, 17(14):1067-1075.
44. Li W., Nie S., Xie M., Chen Y., Li C., Zhang H. Amajor green tea component, (-)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. JAgric Food Chem 2010, 58(16):8977-8982.
45. Zheng J., Lee H.C., Bin Sattar M.M., Huang Y., Bian J.S. Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. Eur J Pharmacol 2011, 652(1-3):82-88.
46. Schmitt N.C., Rubel E.W., Nathanson N.M. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. JNeurosci 2009, 29(12):3843-3851.
47. Peng Z., Xu Z.W., Wen W.S., Wang R.S. Tea polyphenols protect against irradiation-induced injury in submandibular glands' cells: a preliminary study. Arch Oral Biol 2011, 56(8):738-743.
48. Yamamoto T., Staples J., Wataha J., Lewis J., Lockwood P., Schoenlein P., et al. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride. Anticancer Res 2004, 24(5A):3065-3073.
49. Sriram N., Kalayarasan S., Sudhandiran G. Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chem Biol Interact 2009, 180(2):271-280.
50. Sriram N., Kalayarasan S., Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulm Pharmacol Ther 2009, 22(3):221-236.